Risankizumab Skyrizi®
Risankizumab is a humanised IgG1 monoclonal antibody that targets the p19 subunit of interleukin-23. Three SHIKARI® assays are currently available for quantitative drug measurement and qualitative or quantitative anti-risankizumab antibody research. QS-RIS, a specific quantitative assay for free risankizumab, is coming soon.
Why Risankizumab is relevant to biological-drug monitoring research
Risankizumab has clinically important target biology, indication-specific dosing and measurable systemic exposure, making drug concentration and immunogenicity relevant research variables. Scientific source ↗ · EMA source ↗
Molecular Target & Structure
Risankizumab is a humanised IgG1 monoclonal antibody that selectively binds the p19 subunit of interleukin-23 and inhibits IL-23-mediated inflammatory signalling. Source ↗
Approved Indications
EMA-authorised uses include plaque psoriasis, psoriatic arthritis, Crohn’s disease and ulcerative colitis in defined adult populations. EMA source ↗
Steady-State Trough Exposure
FDA pharmacokinetic data show marked regimen-dependent trough exposure across dermatology and IBD indications:
Regulatory exposure values are regimen- and population-specific and are not therapeutic targets. Values vary with dose, timing, formulation and study population. This page is for RUO product information and does not provide clinical guidance.
Four complementary assay formats · QS-RIS coming soon
Enzyme immunoassay for the quantitative determination of free risankizumab in human serum and plasma, developed for concentration measurement between the Cmin and Cmax range.
Pre-release product materials identify QS-RIS as an enzyme immunoassay for the specific and quantitative determination of free risankizumab in human serum and plasma. Final launch specifications and documentation will be added upon release.
Enzyme immunoassay for the qualitative determination of antibodies to risankizumab in human serum and plasma, reported as a positive or negative result.
Enzyme immunoassay for the quantitative determination of antibodies to risankizumab in human serum and plasma, with confirmation as identified in the official product record.
Kit Specifications at a Glance
| Kit Name | Catalog Code | Type | Analyte | ELISA Format | Tests | Storage |
|---|---|---|---|---|---|---|
| SHIKARI® Q-RIS | RIS-FD-SKY | Drug-Level Kit | Free risankizumab | ELISA | 96 | 2–8°C |
| SHIKARI® QS-RIS Coming Soon | RIS-SPEC-RIS | Specific Drug-Level Kit | Free risankizumab | ELISA | 96 | 2–8°C |
| SHIKARI® S-ATRIS | RIS-QLS-SKY | Qualitative ADA Kit | Antibodies to risankizumab | ELISA | 96 | 2–8°C |
| SHIKARI® S-ATRIS | RIS-QNS-SKY | Quantitative ADA Kit | Antibodies to risankizumab | ELISA | 96 | 2–8°C |
* Store currently available assays at +4°C and refer to the current protocol supplied with each kit. Their specifications were verified against the exact official product records. QS-RIS pre-release details are taken from the supplied kit and procedure materials; final launch documentation will govern.
Which kit fits your research question?
Choose an available drug-concentration or anti-drug-antibody assay according to the required analytical output. QS-RIS selection guidance will be finalised at launch.
Risankizumab Literature and Product-Use Records · 1
Ready to order, or need technical guidance?
Matrix Biotek can help identify an available Risankizumab assay, prepare regional quotation and delivery information, or share QS-RIS launch updates. SHIKARI® products are developed and manufactured in Ankara and supported through our European headquarters in Barcelona.